In last trading session, 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) saw 0.46 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $23.26 trading at -$0.24 or -1.02% at ring of the bell on the day assigns it a market valuation of $767.58M. That closing price of FDMT’s stock is at a discount of -6.71% from its 52-week high price of $24.82 and is indicating a premium of 77.13% from its 52-week low price of $5.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.26 million shares which gives us an average trading volume of 490.53K if we extend that period to 3-months.
For 4D Molecular Therapeutics Inc. (FDMT), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.91 in the current quarter.
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) trade information
Upright in the red during last session for losing -1.02%, in the last five days FDMT remained trading in the green while hitting it’s week-highest on Monday, 11/21/22 when the stock touched $23.26 price level, adding 6.29% to its value on the day. 4D Molecular Therapeutics Inc.’s shares saw a change of 6.02% in year-to-date performance and have moved 10.71% in past 5-day. 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) showed a performance of 210.13% in past 30-days. Number of shares sold short was 2.95 million shares which calculate 6.65 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $35.17 to the stock, which implies a rise of 33.86% to its current value. Analysts have been projecting $15.00 as a low price target for the stock while placing it at a high target of $68.00. It follows that stock’s current price would drop -192.35% in reaching the projected high whereas dropping to the targeted low would mean a gain of 35.51% for stock’s current value.
4D Molecular Therapeutics Inc. (FDMT) estimates and forecasts
Statistics highlight that 4D Molecular Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 217.76% of value to its shares in past 6 months, showing an annual growth rate of -26.46% while that of industry is 11.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -11.00% in the current quarter and calculating 3.50% increase in the next quarter. This year revenue growth is estimated to fall -72.20% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $880k for the same. And 4 analysts are in estimates of company making revenue of $2.76 million in the next quarter that will end on Dec 2022. Company posted $1.37 million and $92k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -35.60% while estimating it to be 2,900.00% for the next quarter.
In 2022, company’s earnings growth rate is likely to be around -21.00% while estimates for its earnings growth in next 5 years are of 35.70%.
4D Molecular Therapeutics Inc. is more likely to be releasing its next quarterly report between November 08 and November 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
4D Molecular Therapeutics Inc. (NASDAQ:FDMT)’s Major holders
Insiders are in possession of 11.54% of company’s total shares while institution are holding 82.26 percent of that, with stock having share float percentage of 92.99%. Investors also watch the number of corporate investors in a company very closely, which is 82.26% institutions for 4D Molecular Therapeutics Inc. that are currently holding shares of the company. BVF Inc. is the top institutional holder at FDMT for having 4.01 million shares of worth $27.97 million. And as of Jun 29, 2022, it was holding 12.38% of the company’s outstanding shares.
The second largest institutional holder is Viking Global Investors, L.P., which was holding about 3.94 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 12.16% of outstanding shares, having a total worth of $27.49 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.81 million shares of worth $5.64 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 0.63 million shares on Sep 29, 2022, making its stake of worth around $5.07 million in the company or a holder of 1.95% of company’s stock.